Healthcare [ 13/13 ] | Diagnostics & Research [ 77/164 ]
NASDAQ | Common Stock
Trinity Biotech plc acquires, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe.
The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders.
The company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia.
In addition, the company sells raw materials to the life sciences industry and research institutes.
It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners.
Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Apr 4, 24 | 0.00 Increased by +100.00% | -0.12 Increased by +100.00% |
| Jan 31, 24 | -0.17 Increased by +35.19% | -0.14 Decreased by -25.00% |
| Oct 3, 23 | -0.15 Increased by +34.78% | -0.09 Decreased by -66.67% |
| Jul 6, 23 | -0.15 Decreased by -400.00% | -0.06 Decreased by -150.00% |
| May 2, 23 | -0.06 Increased by +88.00% | -0.06 |
| Mar 23, 23 | -0.27 Decreased by -350.00% | -0.06 Decreased by -350.00% |
| Dec 16, 22 | -0.23 Decreased by -570.35% | -0.04 Decreased by -475.00% |
| Jul 21, 22 | -0.03 Decreased by -114.15% | -0.03 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 14.68 M Decreased by -18.62% | -6.72 M Increased by +33.30% | Decreased by -45.79% Increased by +18.03% |
| Jun 30, 23 | 13.90 M Decreased by -24.73% | -5.99 M Increased by +70.15% | Decreased by -43.09% Increased by +60.35% |
| Mar 31, 23 | 18.04 M Decreased by -7.63% | -10.08 M Decreased by -702.63% | Decreased by -55.87% Decreased by -752.38% |
| Dec 31, 22 | 14.83 M Decreased by -24.05% | -6.30 M Decreased by -477.09% | Decreased by -42.52% Decreased by -596.51% |
| Sep 30, 22 | 18.04 M Decreased by -18.03% | -10.08 M Decreased by -862.76% | Decreased by -55.87% Decreased by -1.03 K% |
| Jun 30, 22 | 18.46 M Decreased by -28.55% | -20.06 M Decreased by -2.46 K% | Decreased by -108.65% Decreased by -3.49 K% |
| Mar 31, 22 | 19.52 M Decreased by -40.41% | 1.67 M Increased by +116.68% | Increased by +8.56% Increased by +127.99% |
| Dec 31, 21 | 19.52 M Decreased by -40.41% | 1.67 M Increased by +116.68% | Increased by +8.56% Increased by +127.99% |